Taletrectinib Continues to Demonstrate High Clinical Activity in Advanced ROS1+ NSCLC

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Related Keywords

New York ,United States ,China ,J Thor Onc ,Christine Bestvina ,Stephenv Liu ,Alexander Drilon ,Jason Porter ,China National Medical Products Administration ,Cancer Center ,University Of Chicago Medicine Comprehensive Cancer Center ,Georgetown University ,National Medical Products Administration Of China ,Research Institute ,Lung Cancer Disease Research Group ,Georgetown Lombardi Comprehensive Cancer Center ,West Cancer Center ,National Medical Products Administration ,Thoracic Oncology ,Developmental Therapeutics ,Georgetown Lombardi Comprehensive Cancer ,Early Drug Development Service ,Memorial Sloan Kettering Cancer Center ,Uchicago Medicine Comprehensive Cancer Center ,Heart Therapeutics ,Anheart Therapeutics ,Ros1 Tki ,Tyrosine Kinase Inhibitor ,Os1 Positive Non Small Cell Lung Cancer ,Nsclc ,2023 Esmo Congress ,Phase 2 Trust Ii Trial ,Taletrectinib ,